Hepatocellular carcinoma (HCC)—closely associated with liver cirrhosis and, in fact, the
main cause of death in patients with such disease—is now recognized as one of the most …

Hepatocellular carcinoma (HCC) is the fifth most common tumor worldwide. Multiple
treatment options are available for HCC including curative resection, liver transplantation …

In the 2010 version of the Japan Society of Hepatology (JSH) consensus-based treatment
algorithm for the management of hepatocellular carcinoma (HCC), transarterial …

Background & Aims We aimed to establish an objective point score to guide the decision for
the first treatment with transarterial chemoembolization (TACE) in patients with …

Recent advancements have improved the management of patients with liver cancer. Results
of studies have informed how to stage and decide the optimal treatment option for each …

In Europe, trans-arterial chemoembolization (TACE) is usually given to patients with
Barcelona Clinic Liver Cancer (BCLC)" intermediate stage" hepatocellular carcinoma …

Transarterial chemoembolization (TACE) and radioembolization (RE) are frequently used to
treat patients with hepatocellular carcinoma who cannot receive curative therapies …

Transarterial chemoembolization (TACE) is the first line treatment for patients with
intermediate stage hepatocellular carcinoma but is also increasingly being used for patients …

Liver cancer was traditionally treated by surgery or interventional ablative treatments, or, if
these options were not feasible, by best supportive care. Since 2008, systemic therapy with …

Palliative therapies for hepatocellular carcinoma (HCC) include transcatheter arterial
embolic therapies, radiation therapy and systemic chemotherapies such as sorafenib …